Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study
Arsène Mekinian,
Jérémie Sellam,
Laure Ricard,
Olivier Fain,
Ariel Cohen,
François Chasset,
Claire de Moreuil,
François Maillot,
Sonia Alamowitch,
Noemie Abisror,
Geoffrey Urbanski,
Alexis F Guedon,
Charlotte Laurent,
Sophie Deriaz,
Grigorios Gerotziafas,
Ismail Elalamy,
Alexandra Audemard,
Jean Jacques Boffa,
Clémentine Wahl
Affiliations
Arsène Mekinian
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Jérémie Sellam
Service de Rhumatologie, CRSA INSERM, UMRS 938, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France
Laure Ricard
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Olivier Fain
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Ariel Cohen
Service de Cardiologie, Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France
François Chasset
Service de Dermatologie et Vénérologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
Claire de Moreuil
Service de Médecine Interne, CHRU de Brest, Brest, France
François Maillot
Service de Médecine Interne, CHRU et université de Tours, Tours, France
Sonia Alamowitch
Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpétrière, AP-HP, Centre de Recherche de Saint Antoine, INSERM, UMRS 938, Sorbonne Université Paris, Paris, France
Noemie Abisror
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Geoffrey Urbanski
Service de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d’Angers, Angers, France
Alexis F Guedon
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Charlotte Laurent
Sorbonne Université,Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU 3iD), Hôpital Saint-Antoine, AP-HP, Paris, France
Sophie Deriaz
Service de Médecine Interne, CHRU et université de Tours, Tours, France
Grigorios Gerotziafas
Service de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
Ismail Elalamy
Service de Hémostase et Hématologie Biologique, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
Alexandra Audemard
Service de Médecine Interne, CHRU et université de Tours, Tours, France
Jean Jacques Boffa
Service de Néphrologie, Hôpital Tenon, AP-HP, Sorbonne Université, Paris, France
Clémentine Wahl
Sorbonne Université, Service d’hématologie biologique, AP-HP, Hôpital Saint-Antoine, Paris, France
Introduction Antiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (arterial, venous or small vessel) or obstetrical events and persistent antiphospholipid antibodies (aPL), according to the Sydney classification criteria. Many studies have performed cluster analyses among patients with primary APS and associated autoimmune disease, but none has focused solely on primary APS. We aimed to perform a cluster analysis among patients with primary APS and asymptomatic aPL carriers without any autoimmune disease, to assess prognostic value.Methods In this multicentre French cohort study, we included all patients with persistent APS antibodies (Sydney criteria) measured between January 2012 and January 2019. We excluded all patients with systemic lupus erythematosus or other systemic autoimmune diseases. We performed hierarchical cluster analysis on the factor analysis of mixed data coordinates results with baseline patient characteristics to generate clusters.Results We identified four clusters: cluster 1, comprising ‘asymptomatic aPL carriers’, with low risk of events during follow-up; cluster 2, the ‘male thrombotic phenotype’, with older patients and more venous thromboembolic events; cluster 3, the ‘female obstetrical phenotype’, with obstetrical and thrombotic events; and cluster 4, ‘high-risk APS’, which included younger patients with more frequent triple positivity, antinuclear antibodies, non-criteria manifestations and arterial events. Regarding survival analyses, asymptomatic aPL carriers relapsed less frequently than the others, but no other differences in terms of relapse rates or deaths were found between clusters.Conclusions We identified four clusters among patients with primary APS, one of which was ‘high-risk APS’. Clustering-based treatment strategies should be explored in future prospective studies.